about header
Press Releases
Print Text Size
  • 3/19/09 1:08 pm EDT
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today announced that the European Medicines Agency’s Committee for Human Medicinal Products (CHMP) has adopted a positive opinion for the marketing authorization of the new phosphate binder Renvela® (sevelamer carbonate) for use in patients with chronic kidney diseas

    more...
  • 3/2/09 4:23 pm EST
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease.

    more...
  • 2/26/09 9:32 am EST
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that the European Commission has approved the production of Myozyme® (alglucosidase alfa) at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. The product will be made commercially available immediately. Myozyme is the only approved treatment for Pompe disease, a progressively debilitating and often fatal inherited disorder.

    more...
  • 2/26/09 9:22 am EST
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Synvisc-One (hylan G-F 20), a product intended for the relief of pain associated with osteoarthritis (OA) of the knee. Synvisc-One is the only single-injection viscosupplement approved for the treatment of OA knee pain in the United States.

    more...
  • 2/20/09 1:45 pm EST
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today reported that the Phase 2 clinical trial of its investigational oral therapy Genz-112638 for Gaucher disease type 1 met its primary endpoint.

    more...
  • 2/19/09 12:39 pm EST
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company’s variation to produce Myozyme® (alglucosidase alfa) at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. The positive CHMP opinion is the final step before formal approval to produce and market Myozyme manufactured at the 4000 L bioreactor scale in the European Union, Norway and Iceland.

    more...
  • 2/11/09 8:51 am EST
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today announced solid fourth-quarter revenue and earnings growth and provided guidance for 2009 that underscored its positive outlook for the year.

    more...
  • 2/3/09 1:28 pm EST
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) announced today that its global corporate headquarters, Genzyme Center, is the 2008 recipient of the Harleston Parker Medal, a unique design award presented periodically by the Boston Society of Architects (BSA) and the City of Boston.

    more...
  • 1/13/09 12:02 pm EST
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) announced today that revenue rose 13 percent in the fourth quarter of 2008 and 21 percent for the year. Fourth quarter estimated revenues were $1.17 billion, reflecting an approximate negative $39 million impact of foreign exchange, compared with $1.04 billion in the same period in 2007. For the year, revenue grew to $4.6 billion from $3.8 billion in 2007. Genzyme expects fourth quarter non-GAAP earnings per diluted share of between $1.01 and $1.04.

    more...
  • 1/12/09 9:00 am EST
    CAMBRIDGE, Mass. & CARLSBAD, Calif.--

    CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced that they have begun two new studies of mipomersen, a novel lipid-lowering drug in late-stage development, and a third is currently screening patients. These three trials will provide additional data on mipomersen in high-risk patient populations.

    more...
Contact Us
 

Media Resources

Tweets

Social Media

Business Wire NewsHQ℠
infoBox